Competition Intensifies As Access Increases For US Biosimilars
AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
You may also be interested in...
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.
Education for healthcare professionals and real-world evidence will be important factors in building trust in Byooviz, Samsung Bioepis and Biogen have told Generics Bulletin, acknowledging it will “take some time” for ophthalmologists to grow more comfortable prescribing biosimilars.
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.